Passage BIO, Inc.
For the period ended Apr 20, 2026. Filed Apr 20, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Apr 20, 2026 · Filed Apr 20, 2026
Use the contents to explore the available documents and sections.
Contents
PBFT02 Program Updates
On April 20, 2026, Passage Bio, Inc. (the “Company*”) announced updated interim data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia caused by progranulin deficiency (“FTD-GRN”)* and provided regulatory and corporate updates.
Updated interim data from FTD-GRN patients treated with PBFT02
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.